The Patient-Centered Outcomes Research Institute (PCORI) intends to issue a PCORI Funding Announcement (PFA) on August 12, 2025, seeking to fund high-quality, patient-centered comparative clinical effectiveness research (CER) studies that focus on rare diseases. This preannouncement provides potential applicants additional time to identify collaborators; obtain patient and stakeholder input on potential studies; and develop responsive, high-quality proposals.
Research Initiative Highlights
PCORI uses the National Institutes of Health's definition of a rare disease, defined as a condition that affects fewer than 200,000 individuals in the United States. Though each disease is rare individually, it is estimated that there are more than 10,000 rare diseases affecting about 30 million Americans. People with many different types of rare diseases and their caregivers often experience similar challenges such as finding reliable information and relevant resources, receiving an accurate diagnosis and gaining access to adequate and appropriate care. This Topical PFA will solicit applications proposed to address patient-centered CER questions that will fill important rare disease research gaps. Applications addressing critical decisional dilemmas that span multiple rare diseases are encouraged.
PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs). The purpose of identifying these SAEs is to encourage submissions to these areas, not to limit submissions to these topics. Applicants addressing one of the below SAEs should identify the area that is best associated with their research approach:
Applications addressing cross-cutting issues that include more than one rare disease diagnosis are encouraged, but studies focusing on a single rare disease are also acceptable. Individual- or cluster-randomized controlled trials are preferred; however, well-specified natural experiments, well-designed prospective or retrospective observational studies, and other innovative CER designs suited to rare disease research will also be considered if rigorous methods are proposed. Applicants are encouraged to pay special attention to issues of intervention implementation with an aim of facilitating widespread uptake of findings after completion of the study by utilizing hybrid effectiveness-implementation approaches. Studies focused on the development of research methods will not be considered responsive. Applicants proposing retrospective observational studies must use and demonstrate access to existing data sources such as registries, patient-powered networks or data networks (e.g., PCORnet®).
Comparators can be systems and/or clinical approaches, which may be pharmacological or nonpharmacological interventions. Comparators targeted to rare disease patients and/or their caregivers are acceptable. Interventions with established efficacy in the general population or interventions developed or adapted for those with rare diseases may be acceptable. Applications proposing novel interventions and/or aiming to develop new technologies (such as mobile apps) or decision support tools/aids will be considered nonresponsive. Adaptations of efficacious interventions used in the general population or similar situation may be responsive, but the level of adaptation must be minimal, clearly described and justified a priori.
Applicants should consider, as appropriate, the full range of clinical and patient-centered outcomes data relevant to patients and other stakeholders. PCORI’s Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research inform the expectations for applicants and the corresponding evaluation of applications submitted in response to this PFA.
This funding announcement will accept applications with direct costs up to 12 million dollars and up to five years in duration. For this funding announcement, applicants may request coverage of patient care costs (including medical products, procedures and care services) for potential funding by PCORI. These costs are included as part of the overall direct cost maximum. For additional information, please see the full announcement upon posting.
PCORI encourages all investigators interested in applying to use this inquiry form to submit questions and request to speak with a PCORI Program Officer.
New Engagement Resource and Expectations: PCORI’s Foundational Expectations for Partnerships in Research
In 2024, PCORI released updated guidance for engagement in research, PCORI's Foundational Expectations for Partnerships in Research. Project teams are expected to address PCORI’s Foundational Expectations when applying for PCORI research funding, developing project and engagement plans for awarded projects and reflecting on engagement during a project to improve and strengthen engagement over time. There will be flexibility in how applicants may address the Foundational Expectations. Additional information, guidance and resources can be found on the PCORI website.
Online System Opens
Aug. 12, 2025, 9 am (ET)
Applicant Town Hall
Aug. 19, 2025; 12 - 1 pm (ET)
View Event
Letter of Intent Deadline
Sept. 23, 2025, 5 pm (ET)
Letter of Intent Status Notification
Oct. 21, 2025, 5 pm (ET)
Application Deadline
Jan. 13, 2026, 5 pm (ET)
Merit Review
March 2026
Awards Announced
July 2026
Earliest Start Date
November 2026
Funds Available Up To
Up to $60 million
Total Direct Costs
Up to $12 million
Maximum Project Period
Up to five years
AI Generated success prediction
1. Patient-Centeredness and Stakeholder Engagement
PCORI places a strong emphasis on research that prioritizes outcomes meaningful to patients. Successful applications often demonstrate:
Active involvement of patients, caregivers, and other stakeholders throughout the research process.
Focus on patient-reported outcomes such as quality of life, symptom management, and functional status.
Engagement strategies that ensure the research addresses real-world patient needs.
2. Comparative Clinical Effectiveness Research (CER)
PCORI funds studies that compare two or more healthcare interventions to determine which works best for specific populations. Successful proposals typically:
Address evidence gaps in clinical decision-making.
Utilize diverse study designs, including randomized controlled trials and observational studies.
Aim to inform healthcare choices by comparing benefits and harms of interventions.
3. Real-World Applicability
Research conducted in real-world settings enhances the generalizability of findings. PCORI favors studies that:
Are implemented in diverse healthcare environments.
Reflect routine clinical practice.
Include populations that are representative of those affected by the health issue under study.
4. Methodological Rigor
Adherence to PCORI's Methodology Standards ensures the credibility of research findings. Successful applications demonstrate:
Robust study designs with appropriate controls.
Clear statistical analysis plans.
Strategies to minimize bias and confounding factors.
5. Focus on Health Equity
Addressing disparities in healthcare outcomes is a priority for PCORI. Successful proposals often:
Target underserved or vulnerable populations.
Incorporate interventions aimed at reducing health disparities.
Engage community partners to ensure cultural relevance and acceptability.
6. Collaborative Partnerships
Collaborations between research institutions and community organizations enhance the relevance and impact of research. PCORI supports projects that:
Leverage the strengths of multiple stakeholders.
Promote co-learning and shared decision-making.
Foster sustainable partnerships beyond the life of the project.
Notable Examples of PCORI-Funded Projects
Maternal Health Equity Studies: PCORI awarded $80.5 million to four large studies addressing maternal health disparities. These projects are co-led by academic and community partners and focus on interventions that tackle both clinical and social determinants of health.
Health Systems Implementation Initiative (HSII): Through HSII, PCORI funded 25 projects with a total of $37 million to implement evidence-based interventions in health systems. Projects include improving antibiotic prescribing practices and integrating weight loss programs into primary care.
Tips for Prospective Applicants
Engage Stakeholders Early: Involve patients, caregivers, and clinicians from the outset to ensure the research addresses their priorities.
Demonstrate Real-World Impact: Highlight how the study's findings will be applicable in everyday clinical settings and benefit diverse populations.
Ensure Methodological Soundness: Align your study design with PCORI's Methodology Standards to enhance the credibility of your research.pcori.org
Address Health Disparities: Design interventions that are culturally sensitive and aim to reduce inequities in healthcare outcomes.
Foster Collaborative Relationships: Build partnerships with community organizations and other stakeholders to enrich the research process and outcomes.
Applications are open to researchers in the USA and worldwide.
Sponsor Institute/Organizations: Patient-Centered Outcomes Research Institute (PCORI)
Sponsor Type: Corporate/Non-Profit
Address: 1333 New Hampshire Avenue NW, Suite 1200 Washington, DC 20036 Phone: (202) 827-7700 | Fax: (202) 355-9558 info@pcori.org
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Sep 23, 2025
Jan 13, 2026
$12,000,000
Affiliation: Patient-Centered Outcomes Research Institute (PCORI)
Address: 1333 New Hampshire Avenue NW, Suite 1200 Washington, DC 20036 Phone: (202) 827-7700 | Fax: (202) 355-9558 info@pcori.org
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.